This Article Full Text Full Text (PDF) All Versions of this Article: 90/10/5639    most recent Author Manuscript (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Marzullo, P. Articles by Grugni, G. Search for Related Content PubMed PubMed Citation Articles by Marzullo, P. Articles by Grugni, G. Related Collections Cardiovascular Endocrinology Obesity Neuroendocrinology and Pituitary

The Impact of Growth Hormone/Insulin-Like Growth Factor-I Axis and Nocturnal Breathing Disorders on Cardiovascular Features of Adult Patients with Prader-Willi Syndrome

Departments of General Medicine (P.M., A.M., A.L.), Neurology (L.P.), and Auxology (A.S., G.G.), Ospedale S. Giuseppe, Istituto Auxologico Italiano, I-28921 Verbania, Italy; Departments of Nuclear Medicine (C.M., R.C.) and Cardiology (C.M., E.E., P.T.), Fondazione S. Maugeri, 27100 Veruno, Italy; and Department of Medical Sciences (R.V.), University of Padua, 35122 Padua, Italy

Address all correspondence and requests for reprints to: Paolo Marzullo, M.D., Ph.D., General Medicine, Ospedale S. Giuseppe, Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Auxologico Italiano, Casella Postale 1, Verbania, Italy I-28921. E-mail: marzullop{at}yahoo.com.

Context: Adult patients with Prader-Willi syndrome (PWS) are prone to develop obesity, GH deficiency (GHD), and their related complications, with cardiopulmonary failure explaining more than half of PWS fatalities.

Objective and Study Participants: This study was undertaken to examine the effect of GHD and sleep breathing disorders on cardiovascular risk factors and heart features of 13 PWS (age 26.9 ± 1.2 yr) and 13 age-, gender-, and body mass index-matched obese individuals (age 26.2 ± 0.8 yr).

Results: Compared with controls, PWS patients had lower GH response to arginine+GHRH, IGF-I levels, triglycerides, total and LDL-cholesterol, insulin, and insulin resistance measured by a homeostatic model approach. Dual-energy x-ray absorptiometry, abdominal computed tomography scans, and polysomnography revealed a greater fat mass, similar abdominal fat, but greater sleep breathing disorders in PWS than obese subjects. Echocardiography showed no systolic or diastolic alteration, although PWS had lower left ventricle (LV) mass (135.7 ± 7.7 vs. 163.5 ± 8.4 g, P < 0.05) and near significantly lower values of LV end-diastole diameter (P = 0.08), compared with obese controls. Baseline radionuclide angiography documented comparable values of systolic and diastolic values between groups. However, adrenergic stimulation with dobutamine caused a lower increase of LV ejection fraction (71.9 ± 1.9 vs. 76.3 ± 1.2%, P < 0.05) and heart rate (103 ± 6.9 vs. 128 ± 2.8 beats/min, P < 0.05) in PWS than obese individuals. By multivariate analysis, nocturnal oxygen desaturation and IGF-I levels were main significant predictors of LV mass and heart rate in PWS patients.

Conclusions: PWS differs from simple obesity by a healthier metabolic profile, impaired nocturnal breathing, decreased heart geometry, and systolic and chronotropic performance. GHD and the predictive role of IGF-I on structural and functional heart parameters suggest a GH/IGF-I-mediated control of cardiac risk in PWS.

This article has been cited by other articles:

				P. Marzullo, C. Marcassa, R. Campini, E. Eleuteri, A. Minocci, A. Sartorio, R. Vettor, A. Liuzzi, and G. Grugni Conditional Cardiovascular Response to Growth Hormone Therapy in Adult Patients with Prader-Willi Syndrome J. Clin. Endocrinol. Metab., April 1, 2007; 92(4): 1364 - 1371. [Abstract] [Full Text] [PDF]